Second to None in Business Excellence: Mary Kay Named #2 on the Forbes 2026 Best Customer Service List

10.2.2026 17:01:00 CET | Business Wire | Press release

Mary Kay Wraps up 2025 with 25 Corporate Reputation Awards

Mary Kay Inc., a global direct sales leader in beauty and skincare innovation, entered 2026 with momentum, securing a top-tier distinction on Forbes’ 2026 Best Customer Service list, where the company ranked #2 overall. The honor follows a standout year for Mary Kay, which concluded 2025 with a total of 25 global awards, underscoring its continued focus on corporate excellence, direct selling industry, social impact, environmental sustainability, science, and innovation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210599426/en/

The recent recognition highlights Mary Kay’s enduring commitment to putting the customer at the heart of everything it does, from seamless digital support to personalized beauty advice. The Forbes Best Customer Service ranking spotlights organizations that have set the gold standard for responsiveness, empathy, and excellence in service delivery – and Mary Kay’s placement at number two reflects a remarkable year of business transformation.

“Every interaction with our customers is an opportunity to make someone feel seen, supported, and valued,” said Ryan Rogers, CEO of Mary Kay Inc. “Climbing to the No. 2 spot in the Forbes ranking is a strong validation of our people-powered culture and demonstrates the significance of what we can accomplish together. It speaks to the second-to-none reputation of our Independent Beauty Consultants, the passion of our customer service teams, and company values built on service and making time for others. That foundation is what inspires us to consistently deliver unforgettable customer experiences through our tried-and-true products.”

“Our Best Customer Service list relies on 3.8 million customer ratings each year to capture how real users rate thousands of brands and products,” said Forbes Assistant Managing Editor Alan Schwarz, who oversees the annual list. “More than 3,500 different brands were reviewed. To even make the top 300 list is an achievement — Mary Kay placing No. 2 overall indicates just how highly its customers feel about the company."

The Forbes recognition is the latest of a series of reputation awards garnered by Mary Kay in 2025:

Corporate Excellence

Forbes #2 | Best Customer Service list
Newsweek | America’s Greatest Workplaces for Women 2025
Newsweek | America’s Greatest Workplaces 2025
WWD Beauty Inc. #11 | The 2024 Top 100 Beauty Companies
Happi #13 | Top 50 U.S. Companies
Forbes Diamonds 2025 – Mary Kay Poland
EXPANSIÓN | 2025 Compliance Awards – Mary Kay Spain
China Association for Business Culture | 2025 Enterprise of Excellence Award – Mary Kay China

Brand Performance

Euromonitor International #1 | Direct Selling Brand of Skin Care and Color Cosmetics in the World¹ for three consecutive years (2023, 2024, 2025)
Euromonitor International #1 Brand of Facial Make-Up in Latin America²
Euromonitor International #1 Brand of Lip Products in Latin America³
Euromonitor International #1 Brand of Skincare and Color Cosmetics in Mexico⁴
Euromonitor International #1 Brand of Color Cosmetics in Mexico⁵
Nielsen | #1 Brand in Foundations in Brazil
Nielsen | #1 Brand in Makeup in Brazil
2025 Superbrands | Mary Kay Slovakia and Mary Kay Czech Republic

Direct Selling & Innovation

Respected Direct Selling Enterprise 2025 Award – Mary Kay China
Direct Selling News (DSN) | 2025 DSN 40 Under 40: Megan Gregg for Legal Excellence
Direct Selling News (DSN) | 2025 DSN 40 Under 40: Julia Santosuosso for Corporate Social Responsibility Impact
German Direct Selling Association (BDD) | “2025 Innovation” Award for Mary Kay’s AI-powered Foundation Finder – Mary Kay Germany

Social Impact & Environmental Sustainability

Forbes #9 | Best Brands for Social Impact list – 2025
Golden Bee | 2025 Outstanding Corporate Sustainability Report for "Gender Equality Information Disclosure” Award – Mary Kay China
Cemefi | Distintivo ESR^®Socially Responsible Company (Empresa Socialmente Responsable) – Mary Kay Mexico (2024, 2025)
The Dallas Entrepreneurship Center (DEC) Network State of Entrepreneurship | “Large Corporation of the Year” Award
Baylor Scott & White Dallas Foundation | “Circle of Care” Award.

***

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 40 markets. For over 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com. Find us on Facebook, Instagram, and LinkedIn, or follow us on X.

About Forbes

Forbes is an iconic global media brand that has symbolized success for over a century. Fueled by journalism that informs and inspires, Forbes spotlights the doers and doings shaping industries, achieving success and making an impact on the world. Forbes connects and convenes the most influential communities ranging from billionaires, business leaders and rising entrepreneurs to creators and innovators. The Forbes brand reaches more than 140 million people monthly worldwide through its trusted journalism, signature ForbesLive events and 49 licensed local editions in 81 countries.

###

¹ “Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data”

² “Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data”

³ “Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data”

⁴ “Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data”

⁵ “Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data”

View source version on businesswire.com: https://www.businesswire.com/news/home/20260210599426/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom